Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Clinical Ophthalmology (Auckland, N.Z.)|February 2, 2023
Reported Rates of Intraocular Inflammation with Intravitreal Aflibercept Administered via Pre-Filled Syringe or from Vials in Clinical Practice Between 2012 and 2022Ursula Schmidt-Ott, Scott Fitzpatrick, Zoran Hasanbasic, et al.
Japanese Journal of Ophthalmology|December 26, 2025
Intravitreal aflibercept 8 mg in patients from Japan with neovascular age-related macular degeneration: 48-week subgroup analysis of the PULSAR trialHideki Koizumi, Shigeru Honda, Tsutomu Yasukawa, et al.
Japanese Journal of Ophthalmology|December 26, 2025
Intravitreal aflibercept 8 mg in patients from Japan with diabetic macular edema: 48-week subgroup analysis of the PHOTON trialKiyoshi Suzuma, Toshinori Murata, Masahiko Shimura, et al.
Ophthalmology and Therapy|June 13, 2026
Intraocular Pressure Outcomes with Intravitreal Aflibercept 8 mg: A 96-Week Pooled Analysis from PULSAR and PHOTONAnat Loewenstein, Ursula Schmidt-Ott, Diana V Do, et al.
Therapeutic Advances in Ophthalmology|August 21, 2025
Plain language summary of publication of the 48-week results from the PULSAR study investigating how well a new dose of aflibercept works and how safe it is for people with wet age-related macular degenerationPaolo Lanzetta, Jean-François Korobelnik, Jeffrey S Heier, et al.
Therapeutic Advances in Ophthalmology|July 14, 2025
Plain language summary of publication of the 48-week results from the PHOTON study: intravitreal aflibercept 8 mg for diabetic macular edemaDavid M Brown, David S Boyer, Diana V Do, et al.
Lancet (London, England)|March 10, 2024
Intravitreal aflibercept 8 mg in neovascular age-related macular degeneration (PULSAR): 48-week results from a randomised, double-masked, non-inferiority, phase 3 trialPaolo Lanzetta, Jean-François Korobelnik, Jeffrey S Heier, et al.
Therapeutic Advances in Ophthalmology|July 6, 2026
Plain language summary of publication of the 96-week results from the PHOTON study: intravitreal aflibercept 8 mg for diabetic macular edemaDiana V Do, Charles C Wykoff, Sobha Sivaprasad, et al.
Ophthalmology|August 28, 2025
Intravitreal Aflibercept 8 mg in Neovascular Age-related Macular Degeneration: 96-Week Results from the Randomized Phase 3 PULSAR TrialJean-François Korobelnik, Paolo Lanzetta, Sergio Leal, et al.
Lancet (London, England)|March 10, 2024
Intravitreal aflibercept 8 mg in diabetic macular oedema (PHOTON): 48-week results from a randomised, double-masked, non-inferiority, phase 2/3 trialDavid M Brown, David S Boyer, Diana V Do, et al.
Pageof 2